Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

SKB reports fibrinogen antagonists

Aug. 16, 1996

Anticoagulant hirudin analogue NF-22 designated developmental candidate

Aug. 16, 1996

Corvas discloses thrombin inhibitors

Aug. 16, 1996

Ortho reveals fibrinogen antagonists

Aug. 9, 1996

Bicyclic fibrinogen antagonists described by SmithKline Beecham

Aug. 9, 1996

Piperazine fibrinogen antagonists from Thomae

Aug. 9, 1996

RO-11 demonstrates efficacy in phase III as DVT prevention agent

Aug. 9, 1996

Thrombin inhibitors inhelabo's pipeline

Aug. 9, 1996

RPR's enoxaparin reduces risk of DVT following hip replacement

Aug. 9, 1996

Hemaseel HMN phase I results announced

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...